ClearFlow, Inc. Receives FDA Clearance for FlowGlide™ Technology for Cardiac Surgery Patients

Anaheim, CA – June 20, 2017 — ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that the United States Food & Drug Administration (FDA) has granted 510[k] clearance for the company’s proprietary FlowGlide™ Active Clearance Technology® System. The FlowGlide™ System is the next generation of ClearFlow’s Active Clearance Technology that prevents or reduces chest drains from occluding with clot, which can lead to retained blood around the heart and lungs. The composite of drainage-related complications that are detrimental to outcomes after cardiothoracic surgery and that may require early or late intervention to remediate is known as Retained Blood Syndrome (RBS). These clinical complications have significant economic

ClearFlow Receives Frost & Sullivan ‘New Product Innovation’ Award for PleuraFlow Technology

Anaheim, CA – April 18, 2017—ClearFlow Inc., a medical device company based in Anaheim, California, has received the prestigious 2017 Global Frost & Sullivan Award for New Product Innovation. The award was presented to ClearFlow for its development of the PleuraFlow® Active Clearance Technology® (ACT®) System, which has been clinically shown to reduce the occurrence of complications after cardiac surgery. Evidence suggests that chest tubes which are used for drainage after cardiac surgery have a high failure rate due to clogging. If the extra blood isn’t removed from inside the chest cavity after surgery, patients may require additional procedures which are known as Retained Blood Syndrome (RBS). Multiple studies have shown

New Study Reveals that All Patients May be at Risk for Retained Blood after Heart Surgery

— ClearFlow Executives Comment on Need for New Protocols —  Anaheim, CA – January 31, 2017—Clinical study results presented at the Society of Critical Care Medicine (SCCM) 46th Annual Critical Care Congress in Honolulu last week suggest that all heart surgery patients are at risk for Retained Blood Syndrome, not just high-risk patients, as previously assumed. All patients having heart surgery are required to have drainage catheters to remove shed blood from around the heart and lungs in the early hours of recovery following surgery.  Evidence suggests that these drainage catheters, or chest tubes, have a high failure rate due to clogging, leading to what is known as Retained Blood

Active Clearance of Chest Tubes Reduces Bleeding Complications After Left Ventricular Assist Device Implantation for Heart Failure

ClearFlow Announces New Clinical Study with Positive Results for the PleuraFlow System Anaheim, CA – November 15, 2016. ClearFlow, Inc., a medical device company based in Anaheim, California has announced the publication of positive results in a clinical trial evaluating the PleuraFlow® Active Clearance Technology® System. Data indicating a marked reduction in Retained Blood Syndrome (RBS) among patients recovering from implantation of left ventricular assist devices (LVAD) was published in the November/December 2016 edition of the American Society of Artificial Internal Organs (ASAIO) Journal (Vol. 62, Issue 66, p. 704-709). Data from the peer-reviewed paper, titled “Active Clearance of Chest Tubes Reduces Re-exploration for Bleeding After Ventricular Assist Device Implantation”

ClearFlow Opens New Distribution Center to Service European Market

Elsloo, THE NETHERLANDS – September 28, 2016 — ClearFlow, Inc., a medical device company headquartered in Anaheim, California and with a European office in Amsterdam, has announced the opening of its new dedicated European Service Center near Maastricht, the Netherlands. ClearFlow is the maker of the PleuraFlow® Active Clearance Technology® System, which proactively prevents or minimizes chest tube clogging. A chest tube that is occluded can lead to retained blood around the heart and lungs, which in turn leads to an increase in likelihood of complications and extended hospital stays. The PleuraFlow System is approved for use in the U.S., Europe, Australia, Brazil, and Canada, and has either cleared or